Patients with end-stage liver disease (ESLD) have complex needs and may benefit from palliative care (PC), which is often underutilized or delayed.
Objectives:
To characterize patients with ESLD who received inpatient PC consultation and to explore differences in characteristics between those who received PC consultation before (pre-Pall) or after (post-Pall) PC participation at weekly liver transplant (LT) Patient Selection Committee (PSC) meetings.
Design:
Single-center retrospective cohort study.
Setting/Subjects:
Hospitalized patients with ESLD who received inpatient PC consultation between February 2017 and February 2019 at an academic LT center in the United States.
Measurements:
PC referral reasons and timing, code status, hospice referrals, discharge location, and mortality.
Results:
Two hundred five patients were included. The primary reason for PC was goals of care (88.8%; n = 182). Most (86.8%; n = 178) were Full Code at hospital admission, while 81% (n = 166) were do-not-resuscitate at discharge. Nearly one quarter (22.9%; n = 47) sought life-prolonging care at discharge, while 41.5% (n = 85) were discharged with hospice, and 34.1% (n = 70) died before discharge. By the end of the study, 85.9% (n = 176) were confirmed as deceased. Median time from PC to hospice referral was 12 days [95% confidence interval [CI]: 8–23]. Median time from PC consult to death was 13 days [95% CI: 9–17] and from hospice referral to death was 7 days [95% CI: 4–13]. There were no statistically significant differences between the pre- and post-Pall groups related to PC referral patterns or outcomes.
Conclusions:
Most PC contacts occurred near end of life, and many led to comfort-focused care. Late referrals may be due to reliance on inpatient consults during acute illness. PC presence at PSC meetings represents an important step in collaboration with LT teams but did not lead to direct impact on PC referral patterns or outcomes.
Get full access to this article
View all access options for this article.
References
1.
D’AmicoG, Garcia-TsaoG, PagliaroL. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol, 2006; 44(1):217–231; doi: 10.1016/j.jhep.2005.10.013
2.
TapperE, ParikhN. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: Observational study. BMJ, 2018; 362:k2817; doi: 10.1136/bmj.k2817
HeronM. Deaths: Leading causes for 2019. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst, 2021; 70(9):1–114.
5.
KwongA, EbelN, KimW, et al.OPTN/SRTR 2020 Annual Data Report: Liver. Wiley-Blackwell: Denmark; 2022; pp. 204–309.
6.
PotosekJ, CurryM, BussM, et al.Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med, 2014; 17(11):1271–1277; doi: 10.1089/jpm.2013.0167
7.
LarsonA, CurtisJ. Integrating palliative care for liver transplant candidates: “Too Well for Transplant, Too Sick for Life.”. J- Am Med Assoc, 2006; 295(18):2168–2176.
8.
WatermanBL, RamseySU, WhitsettMP, et al.Top ten tips palliative care clinicians should know about end-stage liver disease. J Palliat Med, 2021; 24(6):924–931; doi: 10.1089/jpm.2021.0097
9.
BaumannA, WheelerD, JamesM, et al.Benefit of early palliative care intervention in end-stage liver disease patients awaiting liver transplantation. J Pain Symptom Manage, 2015; 50(6):882–886.e2; doi: 10.1016/j.jpainsymman.2015.07.014
10.
BarnesA, WoodmanR, KleinigP, et al.Early palliative care referral in patients with end stage liver disease is associated with reduced resource utilisation. J Gastroenterol Hepatol, 2019; doi: 10.1111/jgh.14877
11.
PatelA, WallingA, Ricks-OddieJ, et al.Palliative care and health care utilization for patients with end-stage liver disease at the end of life. Clin Gastroenterol Hepatol, 2017; 15(10):1612–1619.e4; doi: 10.1016/j.cgh.2017.01.030
12.
AdejumoAC, KimD, IqbalU, et al.Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. Mary Ann Liebert, Inc.: United States; 2020; pp. 97–106.
13.
ChenH, JohnstonA, PalmerA, et al.Too little, too late: Palliation and end-stage liver disease. J Gastroenterol Hepatol, 2021; 36(8):2303–2306; doi: 10.1111/jgh.15499
14.
PoonjaZ, BriseboisA, van ZantenSV, et al.Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol, 2014; 12(4):692–698; doi: 10.1016/j.cgh.2013.08.027
15.
KellySG, CampbellTC, HillmanL, et al.The utilization of palliative care services in patients with cirrhosis who have been denied liver transplantation: A single center retrospective review. Ann Hepatol, 2017; 16(3):395–401; doi: 10.5604/01.3001.0009.8594
16.
KathpaliaP, SmithA, LaiJ. Underutilization of palliative care services in the liver transplant population. World J Transplant, 2016; 6(3):594–598.
17.
OrmanE, YousefA, XuC, et al.Palliative care, patient-reported measures, and outcomes in hospitalized patients with cirrhosis. J Pain Symptom Manage, 2022; 63(6):953–961; doi: 10.1016/j.jpainsymman.2022.02.022
18.
BeckKR, PantilatSZ, O’RiordanDL, et al.Use of palliative care consultation for patients with end-stage liver disease: Survey of liver transplant service providers. J Palliat Med, 2016; 19(8):836–841; doi: 10.1089/jpm.2016.0002
19.
BekelmanD, NowelsC, FischerS, et al.Barriers and facilitators to scaling up outpatient palliative care. J Palliat Med, 2016; 19(4):456–459; doi: 10.1089/jpm.2015.0280
20.
RabowM, SmithA, BraunJ, et al.Outpatient palliative care practices. Arch Intern Med, 2010; 170(7):654–655; doi: 10.1001/archinternmed.2010.56
21.
HarrisPA, TaylorR, ThielkeR, et al.Research Electronic Data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform, 2009; 42(2):377–381; doi: 10.1016/j.jbi.2008.08.010
22.
HarrisPA, TaylorR, MinorBL, et al.; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform, 2019; 95:103208; doi: 10.1016/j.jbi.2019.103208
23.
KamathP, KimW, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology, 2007; 45(3):797–805; doi: 10.1002/hep.21563
HoldenJ, ShamseddeenH, SaitoA, et al.Palliative care and hospice referrals in patients with decompensated cirrhosis: What factors are important? J Palliat Med, 2020; 23(8):1066–1075; doi: 10.1089/jpm.2019.0501
26.
QuinnK, DetskyA, LeeD, et al.Association between palliative care and death at home in adults with heart failure. J Am Heart Assoc, 2020; 9(5):e013844; doi: 10.1161/JAHA.119.013844
27.
BevinsJ, GoksuS, PaulkM, et al.Early palliative care is associated with reduced emergency department utilization in pancreatic cancer. Am J Clin Oncol, 2021; 44(5):181–186; doi: 10.1097/COC.0000000000000802
28.
MichaelN, BealeG, O’CallaghanC, et al.Timing of palliative care referral and aggressive cancer care toward the end-of-life in pancreatic cancer: A retrospective, single-center observational study. BMC Palliat Care, 2019; 18(1):13; doi: 10.1186/s12904-019-0399-4
29.
AgneJ, BertinoE, GroganM, et al.Too many appointments: Assessing provider and nursing perception of barriers to referral for outpatient palliative care. Palliat Med Rep, 2021; 2(1):137–145; doi: 10.1089/pmr.2020.0114
30.
VermaM, KosinskiAS, VolkML, et al.Introducing palliative care within the treatment of end-stage liver disease: The study protocol of a cluster randomized controlled trial. J Palliat Med, 2019; 22(S1):34–43; doi: 10.1089/jpm.2019.0121
31.
van ZylC, StormsA, Van DeenW, et al.Outcomes of palliative care services embedded in a hepatology clinic at a large public hospital (S773). J Pain Symptom Manage, 2020; 59(2):571–571; doi: 10.1016/j.jpainsymman.2019.12.334
32.
WoodrellCD, HansenL, SchianoTD, et al.Palliative care for people with hepatocellular carcinoma, and specific benefits for older adults. Clin Ther, 2018; 40(4):512–525; doi: 10.1016/j.clinthera.2018.02.017
33.
UfereNN, DonlanJ, WaldmanL, et al.Physicians’ perspectives on palliative care for patients with end-stage liver disease: A national survey study. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc, 2019; 25(6):859–869; doi: 10.1002/lt.25469
34.
JohnsonA, ByrielB, RubeckJ, et al.Standardized criteria increases palliative care consultation utilization in patients with end-stage liver disease: A pilot study. Am J Hosp Palliat Care, 2023; 40(7):747–752; doi: 10.1177/10499091221127984
35.
RushB, WalleyK, BrahmaniaM, et al.Palliative care access for hospitalized patients with end-stage liver disease across the United States. Hepatology, 2017; 66(5):1585–1591; doi: 10.1002/hep.29297
36.
WallingA, Schreibeis-BaumH, PimstoneN, et al.Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease. J Palliat Med, 2015; 18(4):378–381; doi: 10.1089/jpm.2014.0265
